Ta4 is a synthetic version of a biologically active, naturally occurring peptide that has been shown, in preclinical studies, to be effective in accelerating dermal, ophthalmic, and myocardial wound healing.
David Crockford, vice president for clinical and regulatory affairs at Regenerx, said: “We are pleased to receive this patent as it expands our intellectual property portfolio by addressing potential disease indications beyond wound healing that may benefit from our drug candidates, in addition to creating a proprietary position through 2023.”